Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-03-31
2003-10-21
Chin, Christopher L. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C422S051000, C422S091000, C422S105000, C422S105000, C422S105000, C435S288300, C435S288400, C436S809000
Reexamination Certificate
active
06635430
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to novel plate devices for use in high-throughput screening assays.
BACKGROUND OF THE INVENTION
The binding of small molecules and peptides to protein is a very important parameter to measure in the pharmaceutical industry. As pharmaceutical companies strive to design novel small molecules and peptides to treat various ailments ranging from life threatening diseases including cancer, AIDS, and heart disease to cosmetic complaints such as ACNE, age spots and wrinkles, successful administration of these drugs through the circulatory system is critical. Many drugs that have been shown to be very active in vitro assays have failed to show efficacy in animal models and in people because of the high plasma protein binding exhibited by these compounds. When a molecule is highly bound to proteins in the blood the amount of drug available to diffuse into the target tissue is significantly reduced and the efficacy of the drug will inevitably be poor.
Whether a small molecule binds to plasma proteins or not usually depends on the size of the molecule, the amino acid composition and the tertiary structure of the molecule. When a small molecule binds to plasma proteins the interaction usually is a result of strong ionic and hydrophobic interactions. Because blood contains several hundred proteins there is a high probability that any small molecule will exhibit some level of binding. Determining the level of binding therefore is critical and will directly correlate with efficacy of the molecule. Predicting whether a molecule is going to show high or low protein binding based on molecular structure has proven to be very difficult. The only sure way to determine whether or not a molecule will exhibit high or low protein binding is to test the molecule directly in a protein-binding assay.
The most common method used to measure the level of protein binding exhibited by compounds is equilibrium dialysis assays. In such assays, a set concentration of drug (usually 1·M) is added to a set volume of human plasma (usually 3 ml). The mixture is added to dialysis tubing with a molecular weight cut-off of 30 kDa. The mixture is allowed to incubate in a large volume of water (usually 4 liter) for 24 hours at 37° C. Following the incubation the sample is collected and the concentration of drug is calculated. If the compound is completely unbound to protein, the concentration following dialysis would be 0, if 50% bound the concentration would be 0.5 uM, etc. Although equilibrium dialysis has been shown to be accurate and consistent, it is very time consuming and the number of drugs a researcher can test in one assay is dependent on how many 4-liter beakers he/she can set up. Thus, the need for a fast, high-throughput assay is needed in the pharmaceutical industry.
SUMMARY OF THE INVENTION
This invention is directed to a filtrate-holder plate comprising polypropylene and Teflon®, most preferably about 2.5% Teflon® and about 97.5% polypropylene. Said plate contains 96 wells each of which is capable of securely holding a Microcon-3, 10, 30 or 100® filter unit (see
FIGS. 4
,
5
,
7
and
8
). Said filter unit (see
FIG. 1
) contains a reservoir and a filter membrane, contained within the filtrate plate. The filter unit also contains a base, which passes through an opening in each of the filtrate plates
96
wells and into a reversible-well collection plate (see
FIGS. 9
,
10
,
11
and
12
). Said “reversible-well collection plate”, also comprises polypropylene and Teflon® (most preferably, again, at about 2.5% Teflon® and about 97.5% polypropylene) and also contains 96 wells. The reversible-well plate is designed such that its wells can accommodate either end of the Micron-3, 10, 30 or 100® filter unit.
The filtrate-holder and reversible-well plates, along with the filter units contained therein, are securely fastened together and used in high-throughout screening assays for the binding of small molecules and peptides to proteins. The design of the plates, and their composition, allows for several advantages in the conducting of such screens, as is described herein.
REFERENCES:
patent: 4154795 (1979-05-01), Thorne
patent: 4427415 (1984-01-01), Cleveland
patent: 4493815 (1985-01-01), Fernwood et al.
patent: 4735778 (1988-04-01), Maruyama et al.
patent: 4770856 (1988-09-01), Uthemann et al.
patent: 4777021 (1988-10-01), Wertz et al.
patent: 4797259 (1989-01-01), Matkovich et al.
patent: 4895706 (1990-01-01), Root et al.
patent: 4948442 (1990-08-01), Manns
patent: 4948564 (1990-08-01), Root et al.
patent: 5084246 (1992-01-01), Lymann et al.
patent: 5200474 (1993-04-01), Chen et al.
patent: 5227137 (1993-07-01), Monti et al.
patent: 5853894 (1998-12-01), Brown
patent: 6309605 (2001-10-01), Zermani
Chin Christopher L.
DuPont Pharmaceuticals Company
Nields & Lemack
LandOfFree
Filtrate plate device and reversible-well plate device does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Filtrate plate device and reversible-well plate device, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Filtrate plate device and reversible-well plate device will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3165696